A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. - Wikidata - awgldk - TriplyDB

A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis.

A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis.

http://www.wikidata.org/entity/Q35171524

about

Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement Tacrolimus (FK506) suppresses TREM-1 expression at an early but not at a late stage in a murine model of fungal keratitis Updates in the treatment of ocular allergies.Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitis Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis.Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis Tacrolimus Ointment for Treatment of Vernal Keratoconjunctivitis.Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis.A Clinical Trial Comparing the Safety and Efficacy of Topical Tacrolimus versus Methylprednisolone in Ocular Graft-versus-Host Disease Treatment of refractory dry eye associated with graft versus host disease with 0.03% tacrolimus eyedrops.Tacrolimus in the treatment of ocular diseases.Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes.Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis.Phase II drugs under investigation for allergic conjunctivitis.Advances in pharmacotherapy for allergic conjunctivitis.An Update on the Therapeutic Approach to Vernal Keratoconjunctivitis.Therapeutic effect of 0.1% Tacrolimus Eye Ointment in Allergic Ocular Diseases.Topical tacrolimus in anterior segment inflammatory disorders.Topical 0.03% tacrolimus for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis.Management of vernal keratoconjunctivitis.Long-term use of 0.003% tacrolimus suspension for treatment of vernal keratoconjunctivitis.Treatment of atopic keratoconjunctivitis in patients with atopic dermatitis: is ocular application of tacrolimus an option?Tacrolimus vs. cyclosporine eyedrops in severe cyclosporine-resistant vernal keratoconjunctivitis: A randomized, comparative, double-blind, crossover study.Relation between total tear IgE and severity of acute seasonal allergic conjunctivitis.Specific IgE in tear fluid and features of allergic conjunctivitis.The efficacy of topical interferon alpha 2b treatment in refractory vernal keratoconjunctivitis.Modulation of postoperative scarring with tacrolimus and octreotide in experimental glaucoma filtration surgery.The role of Staphylococcal enterotoxin in atopic keratoconjunctivitis and corneal ulceration.

P2860

Q26771818-689D1795-5B12-459C-91E9-4681A1763CB2 Q33956479-06A05DDE-0966-4C0C-8D1A-2ABF45313554 Q34612464-D0FDBBD1-BA8E-4098-8307-0123E0AD34A1 Q34620159-B8F2A581-54DE-4B26-A8E3-1150A5534886 Q34882570-80D303D1-2460-4CF6-A4D7-28D28232A550 Q35187578-01E4BACA-FF86-4E8B-AA49-69D090375629 Q35226825-08B5F51D-30C5-43AD-BAEF-66645857CFEB Q36596448-EAA1A4C6-15AE-4F71-A863-25E67F90A38B Q36787750-61A5CA10-384D-4D1D-B927-B3CF39A02756 Q37038747-269A6A98-0E2D-4531-ABF6-249118608C10 Q37208060-935BBF98-B76C-4A76-AB6E-C2E985DC1B3D Q37858514-798FCD43-B0A8-43CA-A45B-3EF84680CE2B Q38179488-53F6D121-4F65-4BB6-A2B2-3BA0CAA43947 Q38184630-4C682F2F-27E7-4760-802D-959158369659 Q38234039-030369E8-5B3A-462A-9D12-92E5880CEBFD Q38460976-7FB4CECE-C37D-4011-ACFF-2B32090D9B0C Q38909557-70BCCBB2-0213-4ACA-A06A-232FA0DE34F9 Q39168929-8B71D85B-788E-4D83-A7C7-3363C44F7E30 Q39175604-11DACCA6-8F93-4615-BB79-339CDA1F87CE Q42227310-FFE6E3B7-72B5-4801-9753-CD1933A676B5 Q42745061-4A351435-10E2-496A-AF47-4B87161E8278 Q46046521-94D99283-A679-492B-838B-FACB8B282975 Q46957199-C8A7A72B-0F94-429D-962D-2678AB827E2A Q48048235-CA80E5D8-61C3-4288-974F-4EEF7ED305F0 Q49188504-9F9909E6-3600-47F1-A192-9C4238F36813 Q50955853-7F31DB2E-37C5-4F6C-A7B4-A10916B94CC7 Q51353842-E1179D0F-9359-41C9-979F-9E746D92E784 Q53185510-35562A17-AD83-4344-B108-2868538D6CF3 Q54315649-3C0209CD-4F4E-48EE-A92A-6EBFD2E5A45A

P2860

A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis.

http://www.wikidata.org/entity/Q35171524

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A randomized, placebo-controll ...... evere allergic conjunctivitis.

@ast

A randomized, placebo-controll ...... evere allergic conjunctivitis.

@en

type

label

A randomized, placebo-controll ...... evere allergic conjunctivitis.

@ast

A randomized, placebo-controll ...... evere allergic conjunctivitis.

@en

prefLabel

A randomized, placebo-controll ...... evere allergic conjunctivitis.

@ast

A randomized, placebo-controll ...... evere allergic conjunctivitis.

@en

P1433

Q35171524-1EE90691-ED56-4845-BF70-60ADCCA9671F

P1476

Q35171524-512411AA-548B-42BE-A339-8A03A352581D

P2093

Q35171524-100AF1E2-192D-49BB-A6E3-29B323B91142

Q35171524-2F0CC7F4-1213-4002-A06C-A9D61EBAD429

Q35171524-308EDB2C-10F9-4F2B-AC60-3C304FB9CBFC

Q35171524-69C22E61-E29E-47BD-9E97-46693C562D43

Q35171524-7B1C889A-C6AE-4E93-AA26-E2B1DA8338D9

Q35171524-8A1EA09D-4094-4D78-B2B5-8A99295F01F1

Q35171524-9172A93E-3235-4472-BAE6-91FBC89128FA

Q35171524-A932C71B-EE24-4367-894F-D8D4C9F7D37D

Q35171524-AE37F52F-5D9F-4A84-979B-B0629306CAA7

Q35171524-AFC0C123-CF07-4181-AC15-757D7AD2786B

P2860

Q35171524-03B8A3B6-4C95-4739-896C-B32EBC12D581

Q35171524-0F2362D9-F8B0-4170-9B0C-DD89ACEF4A53

Q35171524-1533828B-AF1E-496D-87E2-05BA7E92865F

Q35171524-224909E4-B035-4A37-84D3-F1B69C59D58C

Q35171524-25A0016F-3AC4-4C27-8807-3B9B225B855B

Q35171524-34D87077-F0E2-4356-A82C-2A70538DB785

Q35171524-3EB48235-30EE-4A31-861F-C0703C86EA68

Q35171524-4DE532D1-6BC3-4974-9A16-6280AFFF71C6

Q35171524-50EA4057-9ED1-402A-9D09-C059710C32F5

Q35171524-876EA4CA-F46D-46A3-9B3C-04E3CD471B89

P304

Q35171524-B866CCF8-F325-4992-B094-139F90EC3F18

P31

Q35171524-6E056574-B79C-4C3F-9384-603703BB000C

P356

Q35171524-A7FF3831-B2D7-402A-BDE5-25DFF28784C8

P433

Q35171524-8162FA60-0516-416C-A0AB-270EC1643B2F

P478

Q35171524-841D09F5-0742-4EFD-B828-8105718A1ED8

P577

Q35171524-85260178-E7B8-4574-8403-84397712A23E

P5875

Q35171524-7F9DEFA4-70BB-4863-B814-FED0DCB297BD

P698

Q35171524-81C43C3A-BA88-4BDD-AF38-27EEE6B1984C

P921

Q35171524-DE24E2EB-B0CD-4E02-9F75-EBCE3095E46D

P932

Q35171524-1605C9AE-FCDB-4C00-86F4-18F5A42F241C

P356

P1433

Journal of Ocular Pharmacology and Therapeutics

P1476

A randomized, placebo-controll ...... evere allergic conjunctivitis.

@en

P2093

Atsuki Fukushima

http://www.w3.org/2001/XMLSchema#string

Etsuko Takamura

http://www.w3.org/2001/XMLSchema#string

Hiroshi Fujishima

http://www.w3.org/2001/XMLSchema#string

Jun Shoji

http://www.w3.org/2001/XMLSchema#string

Kenichi Namba

http://www.w3.org/2001/XMLSchema#string

Kunihiko Hayashi

http://www.w3.org/2001/XMLSchema#string

Naoki Kumagai

http://www.w3.org/2001/XMLSchema#string

Nobuyuki Ebihara

http://www.w3.org/2001/XMLSchema#string

Shigeki Okamoto

http://www.w3.org/2001/XMLSchema#string

Yayoi Nakagawa

http://www.w3.org/2001/XMLSchema#string

P2860

FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics

Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis.

Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis.

Treatment of severe vernal keratoconjunctivitis with cyclosporine A eyedrops.

Demographic aspects of allergic ocular diseases and evaluation of new criteria for clinical assessment of ocular allergy.

Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children.

Vernal keratoconjunctivitis: Result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment.

A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis.

Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders.

Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study.

P304

165-174

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/JOP.2009.0087

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42388242

http://www.w3.org/2001/XMLSchema#string

P698

20307214

http://www.w3.org/2001/XMLSchema#string

P921

P932

3158389

http://www.w3.org/2001/XMLSchema#string